Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease

Vicky Avery, Fred Buckner, Jonathan Baell, Alan Fairlamb, Paul A. Michels, Rick Tarleton

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    The trypanosomatid protozoa Leishmania, Trypanosoma brucei and Trypanosoma cruzi are the caustive agents of the human diseases respectively, leishmaniasis, African sleeping sickness and Chagas disease. Among the 17 'neglected tropical diseases' highlighted by WHO, progress towards the treatment of these diseases has improved in recent decades, as a result of increased awareness, the emergence of public-private research partnerships and advances in drug-discovery technologies and techniques. Despite this, the current therapies for these diseases have serious shortcomings and, as such, the need to develop novel drugs, improve diagnosis and control the spread of disease is of paramount importance. Future Medicinal Chemistry invited leading experts in the field to share their thoughts and opinions on the changing face of drug discovery in the pursuit of treatments for trypanosomatid-based diseases.
    Original languageEnglish
    Pages (from-to)1709-1718
    Number of pages10
    JournalFuture Medicinal Chemistry
    Volume5
    Issue number15
    DOIs
    Publication statusPublished - Oct 2013

    Fingerprint Dive into the research topics of 'Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease'. Together they form a unique fingerprint.

    Cite this